Skip to main content

Table 3 QALY gained and cost savings of QIV versus TIV

From: Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong

Year QALYs Direct cost Indirect cost Total cost
Age 65–79 years
2001 0.199 1,781 543 2,324
2002* 0 0 0 0
2003 0.291 2,600 792 3,392
2004 21.940 196,311 59,816 256,127
2005 6.670 59,679 18,184 77,863
2006 2.210 19,777 6,026 25,803
2007 22.826 204,241 62,232 266,473
2008 16.370 146,474 44,631 191,105
2010 4.785 42,818 13,047 55,864
Age ≥80 years
2001 0.023 314 96 410
2002* 0 0 0 0
2003 0.581 7,880 2,401 10,281
2004 12.372 167,723 51,105 218,829
2005 3.207 43,477 13,247 56,724
2006 0.829 11,234 3,423 14,657
2007 27.335 370,553 112,907 483,461
2008 19.455 263,741 80,362 344,103
2010 7.425 100,651 30,668 131,319
  1. *In 2002, no influenza B virus was identified from patients admitted to the Prince of Wale Hospital for age groups 65–79 years and ≥80 years. The expected reductions in infected cases, cost-saving and additional QALYs gained with QIV were considered as zero.
\